Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6150)
All Articles published online
|
Publishing Process of This Article
|
Feb 27, 2015 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Gerhard GS, DiStefano JK. Micro RNAs in the development of non-alcoholic fatty liver disease. World J Hepatol 2015; 7(2): 226-234 [PMID: 25729477 DOI: 10.4254/wjh.v7.i2.226] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v7/i2/226.htm |
| Number | Citing Articles |
| 1 |
Giovanni Targher, Christopher D. Byrne. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nature Reviews Nephrology 2017; 13(5): 297 doi: 10.1038/nrneph.2017.16
|
| 2 |
G. Song, H. Vollbrecht. Translating MicroRNAs to the Clinic. 2017; : 93 doi: 10.1016/B978-0-12-800553-8.00005-6
|
| 3 |
Antonella Borrelli, Patrizia Bonelli, Franca Maria Tuccillo, Ira D. Goldfine, Joseph L. Evans, Franco Maria Buonaguro, Aldo Mancini. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. Redox Biology 2018; 15: 467 doi: 10.1016/j.redox.2018.01.009
|
| 4 |
Laura Belloni, Silvia Di Cocco, Francesca Guerrieri, Abigail D. G. Nunn, Silvia Piconese, Debora Salerno, Barbara Testoni, Claudio Pulito, Federica Mori, Matteo Pallocca, Andrea Sacconi, Elisa Vivoli, Fabio Marra, Sabrina Strano, Giovanni Blandino, Massimo Levrero, Natalia Pediconi. Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-31835-2
|
| 5 |
Erica Novo, Claudia Bocca, Beatrice Foglia, Francesca Protopapa, Marina Maggiora, Maurizio Parola, Stefania Cannito. Liver fibrogenesis: un update on established and emerging basic concepts. Archives of Biochemistry and Biophysics 2020; 689: 108445 doi: 10.1016/j.abb.2020.108445
|
| 6 |
Jian Zhang, Catherine A Powell, Matthew K Kay, Ravi Sonkar, Sunitha Meruvu, Mahua Choudhury. Effect of Chronic Western Diets on Non-Alcoholic Fatty Liver of Male Mice Modifying the PPAR-γ Pathway via miR-27b-5p Regulation. International Journal of Molecular Sciences 2021; 22(4): 1822 doi: 10.3390/ijms22041822
|
| 7 |
Shaimaa H. Gadallah, Sanaa Eissa, Hala M. Ghanem, Emad K. Ahmed, Amany Helmy Hasanin, Manal M. El Mahdy, Marwa Matboli. Probiotic-prebiotic-synbiotic modulation of (YAP1, LATS1 and NF2 mRNAs/miR-1205/lncRNA SRD5A3-AS1) panel in NASH animal model. Biomedicine & Pharmacotherapy 2021; 140: 111781 doi: 10.1016/j.biopha.2021.111781
|
| 8 |
Bo Zhu, Siu-Lung Chan, Jack Li, Kathryn Li, Hao Wu, Kui Cui, Hong Chen. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. Frontiers in Cardiovascular Medicine 2021; 8 doi: 10.3389/fcvm.2021.742382
|
| 9 |
Shuangdong Chen, Yixiao Gu, Qinxue Dai, Yanshu He, Junlu Wang. Spinal miR-34a regulates inflammatory pain by targeting SIRT1 in complete Freund's adjuvant mice. Biochemical and Biophysical Research Communications 2019; 516(4): 1196 doi: 10.1016/j.bbrc.2019.07.002
|
| 10 |
Xu Zhang, Xuetao Ji, Qian Wang, John Zhong Li. New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Protein & Cell 2018; 9(2): 164 doi: 10.1007/s13238-017-0436-0
|
| 11 |
Fan‐He Song, Dai‐Qiang Liu, Ya‐Qun Zhou, Wei Mei. SIRT1: A promising therapeutic target for chronic pain. CNS Neuroscience & Therapeutics 2022; 28(6): 818 doi: 10.1111/cns.13838
|
| 12 |
Qiaozhu Su, Virender Kumar, Neetu Sud, Ram I. Mahato. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. Advanced Drug Delivery Reviews 2018; 129: 54 doi: 10.1016/j.addr.2018.01.009
|
| 13 |
|
| 14 |
Giovanni Musso, Maurizio Cassader, Solomon Cohney, Franco De Michieli, Silvia Pinach, Francesca Saba, Roberto Gambino. Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities. Diabetes Care 2016; 39(10): 1830 doi: 10.2337/dc15-1182
|
| 15 |
Cene Skubic, Živa Drakulić, Damjana Rozman. Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs. Expert Opinion on Drug Metabolism & Toxicology 2018; 14(8): 831 doi: 10.1080/17425255.2018.1492552
|
| 16 |
Alan Eduardo Botello-Manilla, Norberto Carlos Chávez-Tapia, Misael Uribe, Natalia Nuño-Lámbarri. Genetics and epigenetics purpose in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2020; 14(8): 733 doi: 10.1080/17474124.2020.1780915
|
| 17 |
Siti Aishah Sulaiman, Nor I. A. Muhsin, Rahman Jamal. Regulatory Non-coding RNAs Network in Non-alcoholic Fatty Liver Disease. Frontiers in Physiology 2019; 10 doi: 10.3389/fphys.2019.00279
|
| 18 |
Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Abilash Valsala Gopalakrishnan, Ramkumar Katturajan, Sandra Kannampuzha, Reshma Murali, Arunraj Namachivayam, Raja Ganesan, Kaviyarasi Renu, Abhijit Dey, Balachandar Vellingiri, Sabina Evan Prince. Exploring the Regulatory Role of ncRNA in NAFLD: A Particular Focus on PPARs. Cells 2022; 11(24): 3959 doi: 10.3390/cells11243959
|
| 19 |
Reda Albadawy, Sara H. A. Agwa, Eman Khairy, Maha Saad, Naglaa El Touchy, Mohamed Othman, Marwa Matboli. Clinical Significance of HSPD1/MMP14/ITGB1/miR-6881-5P/Lnc-SPARCL1-1:2 RNA Panel in NAFLD/NASH Diagnosis: Egyptian Pilot Study. Biomedicines 2021; 9(9): 1248 doi: 10.3390/biomedicines9091248
|
| 20 |
Bo Zhu, Hao Wu, Kathryn S. Li, Shahram Eisa-Beygi, Bandana Singh, Diane R. Bielenberg, Wendong Huang, Hong Chen. Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis. Vascular Pharmacology 2024; 154: 107249 doi: 10.1016/j.vph.2023.107249
|
| 21 |
Reda Albadawy, Sara H. A. Agwa, Eman Khairy, Maha Saad, Naglaa El Touchy, Mohamed Othman, Mohamed El Kassas, Marwa Matboli. Circulatory Endothelin 1-Regulating RNAs Panel: Promising Biomarkers for Non-Invasive NAFLD/NASH Diagnosis and Stratification: Clinical and Molecular Pilot Study. Genes 2021; 12(11): 1813 doi: 10.3390/genes12111813
|
| 22 |
Maria Vulf, Daria Shunkina, Aleksandra Komar, Maria Bograya, Pavel Zatolokin, Elena Kirienkova, Natalia Gazatova, Ivan Kozlov, Larisa Litvinova. Analysis of miRNAs Profiles in Serum of Patients With Steatosis and Steatohepatitis. Frontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.736677
|
| 23 |
Yuping Wang, Zhichao Liu, Wen Zou, Huixiao Hong, Hong Fang, Weida Tong. Molecular regulation of miRNAs and potential biomarkers in the progression of hepatic steatosis to NASH. Biomarkers in Medicine 2015; 9(11): 1189 doi: 10.2217/bmm.15.70
|
| 24 |
Li Wang, Mengyun Sun, Yue Cao, Lingyu Ma, Yang Shen, Arina Alekseevna Velikanova, Xianan Li, Changhao Sun, Yan Zhao. miR-34a regulates lipid metabolism by targeting SIRT1 in non-alcoholic fatty liver disease with iron overload. Archives of Biochemistry and Biophysics 2020; 695: 108642 doi: 10.1016/j.abb.2020.108642
|
| 25 |
Johanna K. DiStefano, Glenn S. Gerhard. Circulating microRNAs in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2016; 10(2): 161 doi: 10.1586/17474124.2016.1125290
|
| 26 |
Mohamed Zaiou. Peroxisome Proliferator-Activated Receptor-γ as a Target and Regulator of Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease. Cells 2023; 12(8): 1205 doi: 10.3390/cells12081205
|
| 27 |
Fatemeh Kalaki-Jouybari, Mehrnoosh Shanaki, Maryam Delfan, Sattar Gorgani-Firouzjae, Soheyla Khakdan. High-intensity interval training (HIIT) alleviated NAFLD feature via miR-122 induction in liver of high-fat high-fructose diet induced diabetic rats. Archives of Physiology and Biochemistry 2020; 126(3): 242 doi: 10.1080/13813455.2018.1510968
|
| 28 |
Arshad Mehmood, Lei Zhao, Yong Wang, Fei Pan, Shuai Hao, Huimin Zhang, Asra Iftikhar, Muhammad Usman. Dietary anthocyanins as potential natural modulators for the prevention and treatment of non-alcoholic fatty liver disease: A comprehensive review. Food Research International 2021; 142: 110180 doi: 10.1016/j.foodres.2021.110180
|
| 29 |
Victor Constantin Stoica, Dimitri Apostol, Mihai Mircea Diculescu, Iuliana Petronela Gârdan, Daniel Adrian Gârdan, Ion Mărunțelu, Ileana Constantinescu. Time for micro-RNAs in steatotic liver disease: a case–control study. Frontiers in Endocrinology 2024; 15 doi: 10.3389/fendo.2024.1349524
|
| 30 |
Qianying Zuo, Nicole Hwajin Park, Jenna Kathryn Lee, Ashlie Santaliz-Casiano, Zeynep Madak-Erdogan. Navigating nonalcoholic fatty liver disease (NAFLD): Exploring the roles of estrogens, pharmacological and medical interventions, and life style. Steroids 2024; 203: 109330 doi: 10.1016/j.steroids.2023.109330
|
| 31 |
W Shan, L Gao, W Zeng, Y Hu, G Wang, M Li, J Zhou, X Ma, X Tian, J Yao. Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease. Cell Death & Disease 2015; 6(7): e1833 doi: 10.1038/cddis.2015.196
|
| 32 |
Luca Valenti, Serena Pelusi. Non-Alcoholic Fatty Liver Disease. 2020; : 129 doi: 10.1007/978-3-319-95828-6_7
|
| 33 |
Somaya Albhaisi, Arun J. Sanyal. Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date. Pharmaceutical Medicine 2019; 33(6): 451 doi: 10.1007/s40290-019-00305-z
|
| 34 |
Soraiya Ebrahimpour-Koujan, Amir Ali Sohrabpour, Edward Giovannucci, Akram Vatannejad, Ahmad Esmaillzadeh. Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trial. Nutrition Journal 2024; 23(1) doi: 10.1186/s12937-024-00911-x
|
| 35 |
Marwa Matboli, Shaimaa H. Gadallah, Wafaa M. Rashed, Amany Helmy Hasanin, Nada Essawy, Hala M. Ghanem, Sanaa Eissa. mRNA-miRNA-lncRNA Regulatory Network in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences 2021; 22(13): 6770 doi: 10.3390/ijms22136770
|
| 36 |
Mohammed Eslam, Luca Valenti, Stefano Romeo. Genetics and epigenetics of NAFLD and NASH: Clinical impact. Journal of Hepatology 2018; 68(2): 268 doi: 10.1016/j.jhep.2017.09.003
|
| 37 |
Mona A Hegazy, Ibrahim Abd ALgwad, Soheir Abuel Fadl, Mohamed Sayed Hassan, Laila Ahmed Rashed, Maha A Hussein. Serum Micro-RNA-122 Level as a Simple Noninvasive Marker of MAFLD Severity. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2021; : 2247 doi: 10.2147/DMSO.S291595
|